Anaplastic Lymphoma Kinase (ALK) Inhibitors Market by Type and Geography - Forecast and Analysis 2021-2025

The anaplastic lymphoma kinase inhibitors market share is expected to increase by USD 3.43 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 21.74%.

This anaplastic lymphoma kinase inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers anaplastic lymphoma kinase inhibitors market segmentations by type (second-generation ALK inhibitors, first-generation ALK inhibitors, and third-generation ALK inhibitors) and geography (North America, Europe, Asia, and ROW). The anaplastic lymphoma kinase inhibitors market report also offers information on several market vendors, including Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc. among others.

What will the Anaplastic Lymphoma Kinase Inhibitors Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Anaplastic Lymphoma Kinase Inhibitors Market Size for the Forecast Period and Other Important Statistics

 

Anaplastic Lymphoma Kinase Inhibitors Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The high target affinity and specificity of alk inhibitors is notably driving the anaplastic lymphoma kinase inhibitors market growth, although factors such as preference for substitute products may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the anaplastic lymphoma kinase inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Anaplastic Lymphoma Kinase Inhibitors Market Driver

The high target affinity and specificity of ALK inhibitors is one of the key factors driving the growth of the global anaplastic lymphoma kinase inhibitors market. Although there are many approved therapies for several carcinomas, pharmacokinetics and pharmacodynamics of the treatment landscape for advanced or recurring carcinomas such as NSCLC still have space for improvement. Most of the available therapies have adverse effects, which reduce patient adherence toward the treatment. ALK inhibitors are a type of drug that acts on tumors with variations of ALK such as an echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocations. Moreover, nucleophosmin (NPM)-ALK is a different variation of ALK that drives anaplastic large-cell lymphomas (ALCLs) and is the target of other ALK inhibitors. ALK inhibitors are known to demonstrate promising results in NSCLC treatments, which is further promoting the R&D teams to conduct research for other applications such as neurologic conditions. Unlike conventional therapies, these drugs work directly on the target, and hence their efficacy is higher than the conventional treatments. The MoA of this drug class is target-specific, which makes it a potential single solution for NSCLC among both medical practitioners as well as patients, which drives the market growth.

Key Anaplastic Lymphoma Kinase Inhibitors Market Trend

The expansion of research areas and combination therapies will fuel the global anaplastic lymphoma kinase inhibitors market growth. ALK inhibitors have demonstrated efficacy in oncology indications such as NSCLC, which has been encouraging vendors to extend their application to various other oncology indications through additional clinical trials. Such extension of application will eventually broaden the patient base for ALK inhibitors, thereby supporting the growth momentum of the overall market. In order to increase their efficacy in the treatment of cancer, some vendors are also conducting clinical trials to study their effects in combination therapies. For instance, in May 2017, MedImmune (a subsidiary of AstraZeneca) initiated Phase I/II study of ensartinib, in combination with durvalumab (immune checkpoint inhibitor), in patients with ALK-rearranged (ALK-positive NSCLC). Such combination therapies are demonstrating promising results and are very likely to be approved soon. Also, expansion in the research areas of ALK inhibitors will have a substantial impact on the global ALK inhibitors market during the forecast period.

Key Anaplastic Lymphoma Kinase Inhibitors Market Challenge

The preference for substitute products is a major challenge for the global anaplastic lymphoma kinase inhibitors market growth. The treatment landscape of carcinomas is vast and is developing very fast with a variety of options such as radiation therapy, surgery, and laser therapy, along with therapeutic options such as targeted therapies and biologics. Currently, the market has only five ALK inhibitors, and their approval is limited to treating only NSCLC. Moreover, the landscape of NSCLC is dominated by chemotherapy and generic small molecule drugs. In addition, the market is experiencing a trend of moving to biological therapy. These alternative treatment options have also proven to be more efficient than the available ALK inhibitors. Hence, these alternatives are preferred as the first-line therapy for the treatment of several oncology conditions, including NSCLC. Furthermore, biological medications have minimum to negligible adverse effects, which add to their advantage in the treatment of carcinomas. Hence, the preference for alternative treatments is posing a major challenge to the global ALK inhibitors market.

This anaplastic lymphoma kinase inhibitors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the ALK inhibitors market as a part of the pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the anaplastic lymphoma kinase inhibitors market during the forecast period.

Who are the Major Anaplastic Lymphoma Kinase Inhibitors Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Betta Pharmaceuticals Co. Ltd.
• Bio-Techne Corp.
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
• F. Hoffmann-La Roche Ltd.
• Helsinn Healthcare SA
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Turning Point Therapeutics Inc.

 

This statistical study of the anaplastic lymphoma kinase inhibitors market encompasses successful business strategies deployed by the key vendors. The anaplastic lymphoma kinase inhibitors market is concentrated and the vendors are deploying growth strategies such as new drugs to compete in the market.

Product Insights and News

• Betta Pharmaceuticals Co. Ltd. - The company is involved in developing X-396. This molecule is under clinical phase II and evaluated as an ALK inhibitor for lung cancer.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The anaplastic lymphoma kinase inhibitors market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Anaplastic Lymphoma Kinase Inhibitors Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the anaplastic lymphoma kinase inhibitors market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the global pharmaceuticals market includes the following core components:

• Inputs
• Inbound logistics
• Operations
• Outbound logistics
• Marketing and sales
• Service
• Support activities
• Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Anaplastic Lymphoma Kinase Inhibitors Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for anaplastic lymphoma kinase inhibitors market in North America. Market growth in this region will be faster than the growth of the market in regions.

The high target affinity and specificity of ALK inhibitors will facilitate the anaplastic lymphoma kinase inhibitors market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 affected all countries in North America, especially the US. The COVID-19 pandemic negatively impacted the ALK inhibitors market in North America. A rise in the number of COVID-19 cases in the second wave of the outbreak in the first quarter of 2021 led to partial lockdowns in several countries, including Canada, and Mexico. Thus, various non-urgent treatments worked in either limited capacity or were completely closed as per the situational guidelines. Some of the scheduled treatments were either delayed or postponed. Hence, the adoption of drugs such as ALK inhibitors used for treating NSCLC witnessed slag, which will impact the market growth in the first half of the forecast period.

What are the Revenue-generating Type Segments in the Anaplastic Lymphoma Kinase Inhibitors Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The anaplastic lymphoma kinase inhibitors market share growth by the second-generation ALK inhibitors segment will be significant during the forecast period. The growth of this segment is majorly driven by the high prevalence of lung cancer. For instance, according to the CDC, 218,527 new cases of lung and bronchus cancer were reported, and 153,718 people died due to the disease in the US in 2015. For every 100,000 people, 58 new lung and bronchus cancer cases were reported, and 41 died due to the disease.

This report provides an accurate prediction of the contribution of all the segments to the growth of the anaplastic lymphoma kinase inhibitors market size and actionable market insights on post COVID-19 impact on each segment.

Anaplastic Lymphoma Kinase Inhibitors Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 21.74%
Market growth 2021-2025	$ 3.43 billion
Market structure	Concentrated
YoY growth (%)	20.14
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 41%
Key consumer countries	US, UK, Japan, Germany, and Canada
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Anaplastic Lymphoma Kinase Inhibitors Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive anaplastic lymphoma kinase inhibitors market growth during the next five years
• Precise estimation of the anaplastic lymphoma kinase inhibitors market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the anaplastic lymphoma kinase inhibitors industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of anaplastic lymphoma kinase inhibitors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch